SOUL
2025
A Heart Disease Study of Semaglutide in Patients with Type 2 Diabetes (Semaglutide cardiOvascular oUtcomes triaL)
In 9,650 patients with type 2 diabetes and ASCVD, CKD, or both, oral semaglutide reduced major adverse cardiovascular events compared with placebo (HR 0.86, 95% CI 0.77-0.96).
Result
Efficacy: Composite of CV death, nonfatal MI, or nonfatal stroke (3-point MACE)HR 0.86 (95% CI 0.77-0.96) · P = 0.006
Below 1 favours oral semaglutide, above 1 favours placebo.
- Absolute difference
- 1.8 points
- NNT
- 56
Absolute difference and NNT are derived from the event rates.
Also reported: Over mean 47.5 months, a 14% relative risk reduction driven largely by fewer MIs.
- Subtopic
- oral GLP-1 RA
- Design
- Double-blind placebo-controlled RCT, event-driven superiority
- Relevance
- Important: one of several pillars.
- Cited in
- ACC/AHA 2026 CKM
- Source
- McGuire DK, Marx N, Mulvagh SL, et al. N Engl J Med. 2025;392(20):2001-2012.doi 10.1056/NEJMoa2501006
Discussion & critique
MACE benefit modest and driven mainly by the MI component with no reduction in CV or all-cause death, and most patients were not on SGLT2 inhibitors at baseline. First CVOT to show an oral GLP-1 agonist lowers cardiovascular events.